Skip to main content
logo
Serina Therapeutics, Inc. (SER)
NYSEAMERICAN: SER · Real-Time Price · USD
1.817
-0.003 (-0.16%)
May 1, 2026, 4:00 PM EDT - Market closed

Serina Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
0.130.063.150.030.14
Revenue Growth (YoY)
132.14%-98.22%9173.53%-76.39%-60.11%
Cost of Revenue
---0.010.02
Gross Profit
0.130.063.150.020.13
Selling, General & Admin
119.623.895.976.71
Research & Development
13.167.482.391.031.46
Other Operating Expenses
-----0.11
Total Operating Expenses
24.1517.16.2878.06
Operating Income
-24.02-17.05-3.13-6.98-7.93
Interest Expense
-0.21-0.53-0.56-3.34-1.1
Other Non-Operating Income (Expense)
5.046.378.96-0.210.45
Total Non-Operating Income (Expense)
4.835.848.4-3.55-0.65
Pretax Income
-19.2-11.215.27-10.52-8.58
Provision for Income Taxes
0.02----
Net Income
-19.18-11.145.27-10.46-8.68
Minority Interest in Earnings
-0.03-0.07--0.06-0
Earnings From Discontinued Operations
-----0.11
Net Income to Common
-19.18-11.145.27-10.46-8.68
Shares Outstanding (Basic)
107221
Shares Outstanding (Diluted)
107721
Shares Change (YoY)
38.47%0.11%242.70%99.12%0.58%
EPS (Basic)
-1.91-1.512.36-1.25-8.09
EPS (Diluted)
-1.91-1.510.73-1.25-8.09
Shares Outstanding
10.779.422.412.171.08
Free Cash Flow
-18.01-17.16-2.98-5.94-15.62
Free Cash Flow Per Share
-1.77-2.33-0.41-2.77-14.50
Gross Margin
100.00%100.00%100.00%61.76%86.81%
Operating Margin
-18478.50%-30442.90%-99.24%-20514.70%-5509.03%
Profit Margin
-14780.80%-20012.50%167.11%-30947.10%-6031.25%
FCF Margin
-13856.90%-30641.10%-94.51%-17467.60%-10847.20%
EBITDA
-23.75-16.63-2.87-6.84-7.8
EBITDA Margin
-18266.20%-29691.10%-90.87%-20126.50%-5418.06%
EBIT
-24.02-17.05-3.13-6.98-7.93
EBIT Margin
-18478.50%-30442.90%-99.24%-20514.70%-5509.03%
Effective Tax Rate
-0.09%0.00%0.00%0.00%0.00%
Updated Mar 25, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q